UNSPSC 51281905: Plicamycin

This classification denotes an antineoplastic antibiotic and dna minor groove binding agent and bone resorption inhibitor with the molecular formula C52H76O24, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NIJ123W41V, chemically known as 1(2h)-anthracenone, 6-((2,6-dideoxy-3-o-(2,6-dideoxy-beta-d-arabino-hexopyranosyl)-beta-d-arabino-h)-2-((o-2,6-dideoxy-3-c-methyl-beta-d-ribohexopyranosyl-(1,4)-o-2,6-dideoxy-alpha-d-lyxo-hexpyranosyl-(1-3)-2,6-dideoxy-beta-d-arabino-hexpyranosyl)oxy)-3-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-3,4-dihydro-8,9-dihydroxy-7-methyl-, (2s-alpha,3beta(1r*,3r*4s*)))- but generally known as plicamycin, which bears US NIH Compound Identifier 29051.

UNSPSC 51281905 Plicamycin, a Commodity code, covers pharmaceutical procurement and supply agreements that state and local governments use to acquire specialty medications and manage pharmacy benefit programs. Recent solicitations under this code reflect state health agencies' efforts to reshape pharmaceutical supply chains through direct-to-manufacturer contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations. The Texas Health and Human Services Commission issued the most recent activity in this space—a Request for Information on its Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—signaling state-level interest in negotiated net pricing models and outcomes-based agreements for prescription fulfillment. State health and human services departments are the primary issuing bodies under this code, focused on optimizing pharmacy benefit delivery and controlling medication costs for employee and retiree health plans.

Texas represents the geographic center of recent activity under this code. The HHS Commission's RFI, posted April 3, 2026, sought vendor capabilities for direct manufacturer relationships and market intelligence on alternative contracting structures outside conventional PBM and GPO arrangements. The RFI functioned as an exploratory procurement mechanism rather than a formal competitive solicitation, designed to inform the state's future procurement strategy before issuing a formal RFP with established financial and temporal parameters. No award values, budget ranges, set-asides, or binding timelines were specified in the RFI materials, reflecting the state's foundational research phase on available solutions and vendor capabilities.